

smith & hopon, p.a.

Intellectual Property Law Patents Trademarks Copyrights

IRW

November 24, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicants: George Blanck et al.
Serial No.: 10/711,101
Filing Date: 08/23/2004
For: OCT-1 as an Oncoprotein
Our Reference No.: 1372.183.PRC

Examiner: Unassigned
Art Unit: 1645

Dear Sir:

Enclosed please find the following:

1. Information Disclosure Statement By Applicants- 2 pages;
2. A copy of the front cover of one (1) U.S. Patent Document;
3. A copy of one (1) Non-Patent Literature Document; and
4. Self-addressed, postage prepaid post card to serve as a receipt for items 1-3.

Very respectfully,

SMITH & HOPEN

By: Ronald E. Smith
ron.smith@smithhopen.com

RES/cm
enclosure


CERTIFICATE OF MAILING
(37 C.F.R. 1.8)

I HEREBY CERTIFY that this correspondence is being mailed with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 24, 2004.

Date: November 24, 2004

Charlene Morgan

Attorney-Client Privileged Communication



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/711,101
Filing Date	08/23/2004
First Named Inventor	George Blanck
Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	1372.183.PRC

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2	OSBORNE, AARON ET AL., Histone Deacetylase Activity Represses Gamma Interferon-Inducible HLA-DR Gene Expression...,Molecular and Cell Biology, 2001, 6495-6506, 21(19).	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.